BR0314304A - Drogas e derivados de triazapiro[5.5]undecano compreendendo o mesmo como o ingrediente ativo - Google Patents
Drogas e derivados de triazapiro[5.5]undecano compreendendo o mesmo como o ingrediente ativoInfo
- Publication number
- BR0314304A BR0314304A BR0314304-0A BR0314304A BR0314304A BR 0314304 A BR0314304 A BR 0314304A BR 0314304 A BR0314304 A BR 0314304A BR 0314304 A BR0314304 A BR 0314304A
- Authority
- BR
- Brazil
- Prior art keywords
- diseases
- allergic
- drugs
- derivatives
- active ingredient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
"DROGAS E DERIVADOS DE TRIAZAPIRO [5.5] UNDECANO COMPREENDENDO O MESMO COMO O INGREDIENTE ATIVO". Um composto representado pela seguinte fórmula geral (I): (em que cada símbolo é como definido na descrição), seu sal de amónio quaternário, seu N-óxido ou uma sal do mesmo. Compostos representados pela fórmula geral (I) são úteis em prevenir e/ou tratar várias doenças inflamatórias (asma, nefrite, nefropatia, hepatite, artrite, artrite reumatóide, rinite, conjuntivite, colite ulcerativa etc), doenças imunes (doenças auto-imunes, rejeição de transplante, imunossupressão, psoríase, esclerose múltipla etc), infecção com vírus da imunodeficiência humana (síndrome da imunodeficiência adquirida), doenças alérgicas (dermatite atópica, urticária, aspergilose broncopulmonar alérgica, gastroenterite eosinofílica alérgica etc), injúria de reperfusão isquêmica, síndrome de distress respiratório agudo, choque acompanhado de infecção bacteriana, diabetes, metástase de câncer etc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002270849 | 2002-09-18 | ||
PCT/JP2003/011834 WO2004026873A1 (ja) | 2002-09-18 | 2003-09-17 | トリアザスピロ[5.5]ウンデカン誘導体およびそれらを有効成分とする薬剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0314304A true BR0314304A (pt) | 2005-07-26 |
Family
ID=32024865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0314304-0A BR0314304A (pt) | 2002-09-18 | 2003-09-17 | Drogas e derivados de triazapiro[5.5]undecano compreendendo o mesmo como o ingrediente ativo |
Country Status (15)
Country | Link |
---|---|
US (1) | US20050267114A1 (pt) |
EP (1) | EP1541574A4 (pt) |
JP (1) | JPWO2004026873A1 (pt) |
KR (1) | KR20050057408A (pt) |
CN (1) | CN1688577A (pt) |
AU (1) | AU2003272879A1 (pt) |
BR (1) | BR0314304A (pt) |
CA (1) | CA2497903A1 (pt) |
MX (1) | MXPA05002771A (pt) |
NO (1) | NO20051379L (pt) |
PL (1) | PL376154A1 (pt) |
RU (1) | RU2005111225A (pt) |
TW (1) | TW200413372A (pt) |
WO (1) | WO2004026873A1 (pt) |
ZA (1) | ZA200502222B (pt) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004026874A1 (ja) * | 2002-09-18 | 2004-04-01 | Ono Pharmaceutical Co., Ltd. | トリアザスピロ[5.5]ウンデカン誘導体の新規結晶 |
TW201018661A (en) | 2003-03-14 | 2010-05-16 | Ono Pharmaceutical Co | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient |
WO2004094424A1 (ja) * | 2003-04-21 | 2004-11-04 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその用途 |
US7498346B2 (en) * | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
ES2457041T3 (es) | 2004-09-13 | 2014-04-24 | Ono Pharmaceutical Co., Ltd. | Derivados de N-4-piperidilurea y medicamentos que los contienen como principio activo |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
EP1874295A4 (en) | 2005-04-20 | 2009-08-12 | Merck & Co Inc | benzothiophene |
CA2603986A1 (en) | 2005-04-20 | 2006-11-02 | Merck & Co., Inc. | Benzothiophene hydroxamic acid derivatives |
JP2008536924A (ja) | 2005-04-20 | 2008-09-11 | メルク エンド カムパニー インコーポレーテッド | ベンゾチオフェンヒドロキサミン酸のカーバメート、ウレア、アミドおよびスルホンアミド置換誘導体 |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
JPWO2006129679A1 (ja) * | 2005-05-31 | 2009-01-08 | 小野薬品工業株式会社 | スピロピペリジン化合物およびその医薬用途 |
EP1896395B1 (en) | 2005-06-24 | 2015-07-15 | Merck Sharp & Dohme Corp. | Modified malonate derivatives |
EP2532679B1 (en) | 2005-10-21 | 2017-04-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
AR057579A1 (es) * | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
AU2007221207A1 (en) | 2006-02-28 | 2007-09-07 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase |
JPWO2007105637A1 (ja) * | 2006-03-10 | 2009-07-30 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
US8258141B2 (en) | 2006-04-21 | 2012-09-04 | Novartis Ag | Organic compounds |
EP2013196B1 (en) | 2006-04-26 | 2015-09-16 | Merck Sharp & Dohme Corp. | Disubstituted aniline compounds |
US8119652B2 (en) | 2006-05-18 | 2012-02-21 | Merck Sharp & Dohme Corp. | Aryl-fused spirocyclic compounds |
JP2009544611A (ja) | 2006-07-20 | 2009-12-17 | メルク エンド カムパニー インコーポレーテッド | ヒストン脱アセチル化酵素阻害剤としてのリン誘導体 |
MX2009002527A (es) * | 2006-09-08 | 2009-03-20 | Pfizer Prod Inc | Derivados de eter diarilico y usos de los mismos. |
ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
DE602007011670D1 (de) | 2007-01-10 | 2011-02-10 | Irm Llc | Verbindungen und zusammensetzungen als kanal-aktivierende proteasehemmer |
US20100093777A1 (en) * | 2007-01-25 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Spiro-ring compound |
EA200901489A1 (ru) | 2007-05-07 | 2010-04-30 | Новартис Аг | Органические соединения |
US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
WO2009005638A2 (en) | 2007-06-27 | 2009-01-08 | Merck & Co., Inc. | Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors |
AU2008334629B2 (en) | 2007-12-10 | 2012-04-12 | Novartis Ag | Organic compounds |
EP2300010B1 (en) | 2008-06-10 | 2015-03-04 | Novartis AG | Pyrazine derivatives as epithelial sodium channel blockers |
WO2010009196A1 (en) * | 2008-07-15 | 2010-01-21 | Temple University Of The Commonwealth System Of Higher Education | Synthesis of bis-peptides oligomers comprising at least one n-substituted diketopiperazine as structural moiety |
TW201031406A (en) | 2009-01-29 | 2010-09-01 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
EP2438059A1 (en) | 2009-06-05 | 2012-04-11 | Link Medicine Corporation | Aminopyrrolidinone derivatives and uses thereof |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
MX2012001838A (es) | 2009-08-12 | 2012-02-29 | Novartis Ag | Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion. |
MY162604A (en) | 2009-08-17 | 2017-06-30 | Intellikine Llc | Heterocyclic compounds and uses thereof |
IN2012DN01453A (pt) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
CA2777245A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
US9035072B2 (en) | 2010-04-22 | 2015-05-19 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
WO2011143444A2 (en) * | 2010-05-14 | 2011-11-17 | President And Fellows Of Harvard College | Diphenylbutypiperidine autophagy inducers |
SG186989A1 (en) | 2010-07-14 | 2013-02-28 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
EP2755976B1 (en) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors |
EP2755967B1 (en) | 2011-09-16 | 2015-10-21 | Novartis AG | Heterocyclic compounds for the treatment of cystic fibrosis |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
WO2013105063A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
WO2013105061A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
US9115129B2 (en) | 2012-01-13 | 2015-08-25 | Novartis Ag | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists |
CN104053659B (zh) | 2012-01-13 | 2016-11-09 | 诺华股份有限公司 | 用于治疗肺动脉高压(pah)及相关病症的作为ip 受体激动剂的稠合的吡咯类 |
US20140378463A1 (en) | 2012-01-13 | 2014-12-25 | Novartis Ag | IP receptor agonist heterocyclic compounds |
EP2802584B1 (en) | 2012-01-13 | 2015-11-18 | Novartis AG | Salts of an ip receptor agonist |
RU2502738C2 (ru) * | 2012-02-07 | 2013-12-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | 1,6'-ДИАРИЛ-3-АРОИЛ-4-ГИДРОКСИ-1',3'-ДИМЕТИЛСПИРО[ПИРРОЛ-2,5'-ПИРРОЛО[2,3-d]ПИРИМИДИН]-2',4',5(1Н,1'Н,3'Н)-ТРИОНЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
CN104245701A (zh) | 2012-04-03 | 2014-12-24 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
WO2014125413A1 (en) | 2013-02-13 | 2014-08-21 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
PL3424534T3 (pl) | 2014-04-15 | 2021-11-22 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
ES2667424T3 (es) | 2014-04-24 | 2018-05-10 | Novartis Ag | Derivados de pirazina como inhibidores de fosfatidil-inositol-3-quinasa |
BR112016024533A8 (pt) | 2014-04-24 | 2021-03-30 | Novartis Ag | derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas |
US10112926B2 (en) | 2014-04-24 | 2018-10-30 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
AU2015294889B2 (en) | 2014-07-31 | 2018-03-15 | Novartis Ag | Combination therapy |
WO2016140501A1 (en) * | 2015-03-04 | 2016-09-09 | Kainos Medicine, Inc. | Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
TW202110844A (zh) * | 2019-06-04 | 2021-03-16 | 日商第一三共股份有限公司 | 具有二螺二酮哌構造之化合物 |
WO2020250116A1 (en) | 2019-06-10 | 2020-12-17 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
US20220306617A1 (en) | 2019-08-28 | 2022-09-29 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998031364A1 (en) * | 1997-01-21 | 1998-07-23 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
US6288083B1 (en) * | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
AU780419C (en) * | 1999-12-03 | 2005-09-29 | Ono Pharmaceutical Co. Ltd. | Triazaspiro(5.5)undecane derivatives and drugs containing the same as the active ingredient |
CN1291988C (zh) * | 2001-03-19 | 2006-12-27 | 小野药品工业株式会社 | 三氮杂螺[5,5]十一烷衍生物及包含其作为活性成分的药物组合物 |
CN1533390A (zh) * | 2001-03-19 | 2004-09-29 | СҰҩƷ��ҵ��ʽ���� | 包含三氮杂螺[5.5]十一烷衍生物作为活性成分的药物组合物 |
JP2002348288A (ja) * | 2001-05-28 | 2002-12-04 | Ono Pharmaceut Co Ltd | スピロ複素環誘導体およびそれらを有効成分とする薬剤 |
CA2461545A1 (en) * | 2001-10-23 | 2003-05-01 | Ono Pharmaceutical Co., Ltd. | Drugs comprising combination of triazaspiro¬5,5|undecane derivative with cytochrome p450 isozyme 3a4 inhibitor and/or p-glycoprotein inhibitor |
WO2003104233A1 (en) * | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors |
CA2498934C (en) * | 2002-09-13 | 2010-02-23 | University Of Maryland Biotechnology Institute | Compositions for inducing increased levels of .beta.-chemokines and methods of use therefor |
WO2004026874A1 (ja) * | 2002-09-18 | 2004-04-01 | Ono Pharmaceutical Co., Ltd. | トリアザスピロ[5.5]ウンデカン誘導体の新規結晶 |
AU2003282821B2 (en) * | 2002-10-11 | 2010-12-16 | University Of Maryland, Baltimore | Carbohydrate-based synthetic vaccines for HIV |
AU2002354054A1 (en) * | 2002-10-18 | 2004-05-04 | Ono Pharmaceutical Co., Ltd. | Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
EP2364982A1 (en) * | 2003-04-18 | 2011-09-14 | ONO Pharmaceutical Co., Ltd. | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof |
EP1623721A1 (en) * | 2003-05-06 | 2006-02-08 | Ono Pharmaceutical Co., Ltd. | Effector cell function inhibitor |
EP1627048A4 (en) * | 2003-05-16 | 2008-10-15 | Univ Maryland Biotech Inst | Compositions for Downregulating CCR5 Expression and Method of Use Therefor |
CA2573951A1 (en) * | 2003-07-18 | 2005-01-27 | Virochem Pharma Inc. | Spiro compounds and methods for the modulation of chemokine receptor activity |
IL157398A0 (en) * | 2003-08-14 | 2004-02-19 | Hadasit Med Res Service | Pharmaceutical compositions comprising ccr5 antagonists |
-
2003
- 2003-09-17 CA CA002497903A patent/CA2497903A1/en not_active Abandoned
- 2003-09-17 AU AU2003272879A patent/AU2003272879A1/en not_active Abandoned
- 2003-09-17 RU RU2005111225/04A patent/RU2005111225A/ru not_active Application Discontinuation
- 2003-09-17 CN CNA038243865A patent/CN1688577A/zh active Pending
- 2003-09-17 US US10/527,435 patent/US20050267114A1/en not_active Abandoned
- 2003-09-17 KR KR1020057004600A patent/KR20050057408A/ko not_active Application Discontinuation
- 2003-09-17 BR BR0314304-0A patent/BR0314304A/pt not_active IP Right Cessation
- 2003-09-17 TW TW092125573A patent/TW200413372A/zh unknown
- 2003-09-17 JP JP2004537582A patent/JPWO2004026873A1/ja not_active Withdrawn
- 2003-09-17 MX MXPA05002771A patent/MXPA05002771A/es unknown
- 2003-09-17 EP EP03753933A patent/EP1541574A4/en not_active Withdrawn
- 2003-09-17 PL PL03376154A patent/PL376154A1/xx not_active Application Discontinuation
- 2003-09-17 WO PCT/JP2003/011834 patent/WO2004026873A1/ja not_active Application Discontinuation
-
2005
- 2005-03-16 ZA ZA200502222A patent/ZA200502222B/en unknown
- 2005-03-16 NO NO20051379A patent/NO20051379L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2004026873A1 (ja) | 2004-04-01 |
RU2005111225A (ru) | 2005-08-27 |
NO20051379L (no) | 2005-06-17 |
US20050267114A1 (en) | 2005-12-01 |
CN1688577A (zh) | 2005-10-26 |
AU2003272879A1 (en) | 2004-04-08 |
TW200413372A (en) | 2004-08-01 |
KR20050057408A (ko) | 2005-06-16 |
EP1541574A1 (en) | 2005-06-15 |
ZA200502222B (en) | 2005-12-28 |
MXPA05002771A (es) | 2005-06-06 |
CA2497903A1 (en) | 2004-04-01 |
JPWO2004026873A1 (ja) | 2006-01-19 |
EP1541574A4 (en) | 2007-06-20 |
PL376154A1 (en) | 2005-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0314304A (pt) | Drogas e derivados de triazapiro[5.5]undecano compreendendo o mesmo como o ingrediente ativo | |
BRPI0408332A (pt) | derivados heterocìclicos contendo nitrogênio e medicamentos contendo os mesmos como ingrediente ativo | |
BR0016111A (pt) | Derivados de triazaespiro[5,5]undecano e medicamentos contendo os mesmos como ingrediente ativo | |
SG146673A1 (en) | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | |
EA200870344A1 (ru) | Азотсодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента | |
ECSP056195A (es) | Derivados de n-alquinil-2(ariloxi-sustituido)alquiltioamida como fungicidas | |
NO20034148D0 (no) | Triazaspiro[5.5]undekanderivater og legemidler inneholdende disse som den aktive bestanddel | |
NO20074391L (no) | CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter | |
DE602005013922D1 (de) | Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor | |
BRPI0406926A (pt) | Inibidores de polimerase viral | |
NO20064166L (no) | Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter | |
NO20076680L (no) | Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter | |
BR0213594A (pt) | Amidas de ácido nicotìnico e heterociclila e derivados de pirimidina análogos como pesticidas | |
MXPA05013631A (es) | Derivado heterociclico de metilsulfona. | |
EP1621540A4 (en) | HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF | |
NO933558L (no) | Benzimidazoler, legemidler inneholdende disse forbindelser, og fremgangsmåte for deres fremstilling | |
ATE518861T1 (de) | Als pestivirus-inhibitoren geeignete imidazoä1,2- aüpyrroloä3,2-cüpyridinverbindungen | |
DE502004009016D1 (de) | Verwendung von chinaldin-und naphthalinderivaten als kristallisationsmodifikatoren | |
ATE345343T1 (de) | Triazolo(4,5-d)pyrimidinderivate als antithrombotische verbindungen | |
UA93377C2 (ru) | Макроциклические ингибиторы вируса гепатита c | |
TH118203B (th) | ไพริมิดีนที่ถูกแทนที่ด้วยไดอะมิโน | |
TH68971A (th) | กรรมวิธีสำหรับการผลิตสารประกอบพิริดิลเอธิลไธโอ, ตัวแลกเปลี่ยนไอออนดัดแปลง และกรรมวิธีสำหรับการผลิตสารเดียวกันนี้, และกรรมวิธีสำหรับการผลิตสารประกอบบิสฟีนอล | |
TH76471A (th) | สารประกอบอินทรีย์ | |
TH58697B (th) | เกลือของเอเวอร์เมคทินที่ถูกแทนที่ในตำแหน่ง 4" และที่มี คุณสมบัติในการกำจัดศัตรูพืช | |
TH79810A (th) | สารประกอบไพริดาซิโนน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010. |